Last one was undersubscribed with - options expiring Aug 2011, exercise 15c.
Maybe management have learnt something.
This one oversubscribed with options expiring 2016, exercise 9c.
Higher price for shares but a much, much better deal on options. If they had offered that last time I wonder if the uptake would have been substantially more ?
Anyway, these bucks should see them funded for quite awhile, along with the income they are deriving from the research.
I will be interested to see the figure from Roche - next quarterly perhaps ?
Q. where will these new shares be traded - ASX, Frankfurt ? (did we get a NASDAQ listing ? (-:) I never did quite understand where shares came from to trade on the Frankfurt exchange.
PYC Price at posting:
6.7¢ Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)